HER-2/neu as a target for cancer vaccines

Immunotherapy

Volumn 2, Issue 2, 2010, Pages 213-226

  Baxevanis, Constantin N ^a   Voutsas, Ioannis F ^a   Gritzapis, Angelos D ^a   Perez, Sonia A ^a   Papamichail, Michael ^a  

^a NONE

Author keywords

Clinical trial; Combinatorial treatment; Cytotoxic response; DNA vaccine; Helper response; HER 2 neu; Long peptide; Tolerance

Indexed keywords

1 METHYL TRYPTOPHAN; ADENOVIRUS VECTOR; AE37 PEPTIDE; CANCER VACCINE; DENILEUKIN DIFTITOX; DNA VACCINE; E75 PEPTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A2 ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; RECOMBINANT INTERLEUKIN 12; TOLL LIKE RECEPTOR AGONIST; TRASTUZUMAB; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; HER-2 PEPTIDE E75 (369-377), HUMAN; PEPTIDE FRAGMENT; RECOMBINANT VACCINE; SUBUNIT VACCINE; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD8+ T LYMPHOCYTE; CELL THERAPY; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; CYTOTOXIC T LYMPHOCYTE; EX VIVO STUDY; HIGH RISK PATIENT; HUMAN; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; RECURRENT CANCER; REVIEW; SOLID TUMOR; ACTIVE IMMUNIZATION; ANIMAL; BAGG ALBINO MOUSE; FORECASTING; HELPER CELL; IMMUNOLOGY; MOUSE; NEOPLASMS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTO ONCOGENE; TRANSPLANTATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; FORECASTING; GENES, ERBB-2; HUMANS; IMMUNOTHERAPY, ACTIVE; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED BALB C; NEOPLASMS; PEPTIDE FRAGMENTS; RECEPTOR, ERBB-2; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; VACCINES, DNA; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 77953398645     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.09.89     Document Type: Review

References (119)

1. Rosenberg SA: Progress in human tumour immunology and immunotherapy. Nature 411(6835), 380-384 (2001).
2. Rubin I, Yarden Y: The basic biology of HER2. Ann Oncol. 12(Suppl. 1), S3-S8 (2001).
3. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2(2), 127-137 (2001).
4. Press MF, Pike MC, Chazin VR et al.: Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 53(20), 4960-4970 (1993).
5. Ross JS, Fletcher JA, Linette GP et al.: The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8(4), 307-325 (2003).
6. Koeppen HK, Wright BD, Burt AD et al.: Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology 38(2), 96-104 (2001).
7. Curcio C, Khan AS, Amici A et al.: DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice. Cancer Gene Ther. 15(2), 108-114 (2008).
8. Baxevanis CN, Sotiropoulou PA, Sotiriadou NN, Papamichail M: Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy. Cancer Immunol. Immunother. 53(3), 166-175 (2004).
9. Mamalaki A, Gritzapis AD, Kretsovali A et al.: In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu-specifc antibody and the g-chain from Fc(epsilon) RI. Cancer Immunol. Immunother. 52(8), 513-522 (2003).
10. Disis ML, Calenoff E, McLaughlin G et al.: Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 54(1), 16-20 (1994).
11. Kiessling R, Wei WZ, Herrmann F et al.: Cellular immunity to the Her-2/neu protooncogene. Adv. Cancer Res. 85, 101-144 (2002).
12. Ward RL, Hawkins NJ, Coomber D, Disis ML: Antibody immunity to the HER-2/ neu oncogenic protein in patients with colorectal cancer. Hum. Immunol. 60(6), 510-515 (1999).
13. Baxevanis CN, Sotiriadou NN, Gritzapis AD et al.: Immunogenic HER-2/neu peptides as tumor vaccines. Cancer Immunol. Immunother. 55(1), 85-95 (2006).
14. Baxevanis CN, Perez SA, Papamichail M: Cancer immunotherapy. Crit. Rev. Clin. Lab. Sci. 46(4), 167-189 (2009).
15. Disis ML, Bernhard H, Jaffee EM: Use of tumour-responsive T cells as cancer treatment. Lancet 373(9664), 673-683 (2009).
16. Mittendorf EA, Holmes JP, Ponniah S, Peoples GE: The E75 HER2/neu peptide vaccine. Cancer Immunol. Immunother. 57(10), 1511-1521 (2008).
17. Reilly RT, Gottlieb MB, Ercolini AM et al.: HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res. 60(13), 3569-3576 (2000).
18. Derbinski J, Schulte A, Kyewski B, Klein L: Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat. Immunol. 2(11), 1032-1039 (2001).
19. Anderson MS, Venanzi ES, Klein L et al.: Projection of an immunological self shadow within the thymus by the aire protein. Science 298(5597), 1395-1401 (2002).
20. Sakaguchi N, Takahashi T, Hata H et al.: Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 426(6965), 454-460 (2003).
21. Finnish-German APECED Consortium: An autoimmune disease: APECED, caused by mutations in a novel gene featuring two PHD-type zinc-fnger domains. Nat Genet. 17(4), 399-403 (1997).
22. Mapara MY, Sykes M: Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J. Clin. Oncol. 22(6), 1136-1151 (2004).
23. + T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity. Eur. J. Immunol. 34(3), 752-761 (2004).
24. Yasutomo K: The cellular and molecular mechanism of CD4/CD8 lineage commitment. J. Med. Invest. 49(1-2), 1-6 (2002).
25. Rolla S, Nicolo C, Malinarich S et al.: Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J. Immunol. 177(11), 7626-7633 (2006).
26. Ambrosino E, Spadaro M, Iezzi M et al.: Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res. 66(15), 7734-7740 (2006).
27. Knutson KL, Dang Y, Lu H et al.: IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J. Immunol. 177(1), 84-91 (2006).
28. + T cells to the antitumor immune response. J. Exp. Med. 201(10), 1591-1602 (2005).
29. Gritzapis AD, Voutsas IF, Lekka E et al.: Identifcation of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties. J. Immunol. 181(1), 146-154 (2008).
30. + T cells: frst evidence for intratumor apoptotic regulatory T cells. Cancer Res. (2010) (In press).
31. Rolla S, Marchini C, Malinarich S et al.: Protective immunity against neu-positive carcinomas elicited by electroporation of plasmids encoding decreasing fragments of rat neu extracellular domain. Hum. Gene Ther. 19(3), 229-240 (2008).
32. Cipriani B, Fridman A, Bendtsen C et al.: Therapeutic vaccination halts disease progression in BALB-neuT mice: the amplitude of elicited immune response is predictive of vaccine effcacy. Hum. Gene Ther. 19(7), 670-680 (2008).
33. Astolf A, Landuzzi L, Nicoletti G et al.: Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. Am. J. Pathol. 166(4), 1205-1216 (2005).
34. Pannellini T, Forni G, Musiani P: Immunobiology of her-2/neu transgenic mice. Breast Dis. 20, 33-42 (2004).
35. Nanni P, Landuzzi L, Nicoletti G et al.: Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-g and B cell dependent. J. Immunol. 173(4), 2288-2296 (2004).
36. Stevanovic S, Schild H: Quantitative aspects of T cell activation-peptide generation and editing by MHC class I molecules. Semin. Immunol. 11(6), 375-384 (1999).
37. Weinzierl AO, Lemmel C, Schoor O et al.: Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. Mol. Cell Proteomics 6(1), 102-113 (2007).
38. Disis ML, Cheever MA: HER-2/neu oncogenic protein: issues in vaccine development. Crit. Rev. Immunol. 18(1-2), 37-45 (1998).
39. Rongcun Y, Salazar-Onfray F, Charo J et al.: Identifcation of new HER2/neu-derived peptide epitopes that can elicit specifc CTL against autologous and allogeneic carcinomas and melanomas. J. Immunol. 163(2), 1037-1044 (1999).
40. Kono K, Rongcun Y, Charo J et al.: Identifcation of HER2/neu-derived peptide epitopes recognized by gastric cancer-specifc cytotoxic T lymphocytes. Int. J. Cancer 78(2), 202-208 (1998).
41. Fisk B, Blevins TL, Wharton JT, Ioannides CG: Identifcation of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specifc cytotoxic T lymphocyte lines. J. Exp. Med. 181(6), 2109-2117 (1995).
42. + (natural killer T) lymphocytes. Int. J. Cancer 98(6), 864-872 (2002).
43. Gritzapis AD, Perez SA, Baxevanis CN, Papamichail M: Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumour responses in vitro and in vivo. Br. J. Cancer 92(1), 72-79 (2005).
44. Brossart P, Stuhler G, Flad T et al.: Her-2/ neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specifc cytotoxic T lymphocytes. Cancer Res. 58(4), 732-736 (1998).
45. Knutson KL, Schiffman K, Disis ML: Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest. 107(4), 477-484 (2001).
46. Gritzapis AD, Sotiriadou NN, Papamichail M, Baxevanis CN: Generation of human tumor-specifc CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors. Cancer Immunol. Immunother. 53(11), 1027-1040 (2004).
47. Kawashima I, Tsai V, Southwood S, Takesako K, Sette A, Celis E: Identifcation of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res. 59(2), 431-435 (1999).
48. Lekka E. Gritzapis AD, Perez SA et al.: Identifcation and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy. Cancer Immunol. Immunother. DOI: 10.1007/s00262-009-0791-7 (2010) (In press).
49. Peiper M, Goedegebuure PS, Linehan DC, Ganguly E, Douville CC, Eberlein TJ: The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes. Eur. J. Immunol. 27(5), 1115-1123 (1997).
50. Scardino A, Alves P, Gross DA et al.: Identifcation of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors. Eur. J. Immunol. 31(11), 3261-3270 (2001).
51. Shiku H, Wang L, Ikuta Y et al.: Development of a cancer vaccine: peptides, proteins, and DNA. Cancer Chemother. Pharmacol. 46(Suppl.), S77-S82 (2000).
52. Toes RE, Schoenberger SP, van der Voort EI, Offringa R, Melief CJ: CD40-CD40 ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Semin. Immunol. 10(6), 443-448 (1998).
53. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR: Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393(6684), 478-480 (1998).
54. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ: T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393(6684), 480-483 (1998).
55. 2+-calmodulin complex are involved in interferon-g-induced expression of HLA class II molecules on HL-60 cells. Proc. Natl Acad. Sci. USA 85(9), 3120-3124 (1988).
56. Celada A, Maki RA: IFN-g induces the expression of the genes for MHC class II I-A b and tumor necrosis factor through a protein kinase C-independent pathway. J. Immunol. 146(1), 114-120 (1991).
57. + T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J. Immunol. 164(7), 3902-3912 (2000).
58. Anderson BW, Kudelka AP, Honda T et al.: Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides. Cancer Immunol. Immunother. 49(9), 459-468 (2000).
59. Disis ML, Rinn K, Knutson KL et al.: Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood 99(8), 2845-2850 (2002).
60. Fisk B, Hudson JM, Kavanagh J et al.: Existent proliferative responses of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides. Anticancer Res. 17(1A), 45-53 (1997).
61. + T cell clones. Cancer Immunol. Immunother. 50(11), 615-624 (2002).
62. Sotiriadou R, Perez SA, Gritzapis AD et al.: Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope. Br. J. Cancer 85(10), 1527-1534 (2001).
63. + T lymphocytes. Nature 421(6925), 852-856 (2003).
64. Bourgeois C, Tanchot C: CD4 T cells are required for CD8 T cell memory generation. Eur. J. Immunol. 33(12), 3225-3231 (2003).
65. Sun JC, Bevan MJ: Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300(5617), 339-342 (2003).
66. Shedlock DJ, Shen H: Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300(5617), 337-339 (2003).
67. + T cells. Nat. Immunol. 7(5), 475-481 (2006).
68. Lollini PL, Cavallo F, Nanni P, Forni G: Vaccines for tumour prevention. Nat. Rev. Cancer 6(3), 204-216 (2006).
69. 1 induced by IL-4 vaccine is associated with the eradication of experimental metastases. Cancer Res. 58(24), 5812-5817 (1998).
70. Quaglino E, Iezzi M, Mastini C et al.: Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res. 64(8), 2858-2864 (2004).
71. Nanni P, Nicoletti G, De Giovanni C et al.: Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J. Exp. Med. 194(9), 1195-1205 (2001).
72. + tumors. Cancer Res. 58(21), 4902-4908 (1998).
73. Murray JL, Przepiorka D, Ioannides CG: Clinical trials of HER-2/neu-specifc vaccines. Semin. Oncol. 27(6 Suppl. 11), 71-75 (2000).
74. Disis ML, Gooley TA, Rinn K et al.: Generation of T-cell immunity to the HER-2/ neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol. 20(11), 2624-2632 (2002).
75. Knutson KL, Schiffman K, Cheever MA, Disis ML: Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specifc immunity. Clin. Cancer Res. 8(5), 1014-1018 (2002).
76. Czerniecki BJ, Roses RE, Koski GK: Development of vaccines for high-risk ductal carcinoma in situ of the breast. Cancer Res. 67(14), 6531-6534 (2007).
77. Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ: Immunopharmacologic analysis of an autologous, hapten-modifed human melanoma vaccine. J. Clin. Oncol. 22(3), 403-415 (2004).
78. + T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma. Ann. Surg. Oncol. 11(10), 892-899 (2004).
79. Takeuchi H, Morton DL, Elashoff D, Hoon DS: Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. Int. J. Cancer 117(6), 1032-1038 (2005).
80. Tagawa ST, Cheung E, Banta W, Gee C, Weber JS: Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with stage IV melanoma. Cancer 106(6), 1353-1357 (2006).
81. Sanderson K, Scotland R, Lee P et al.: Autoimmunity in a Phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol. 23(4), 741-750 (2005).
82. Kirkwood JM, Ibrahim JG, Sosman JA et al.: High-dose interferon a-2b signifcantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/ S9512/C509801. J. Clin. Oncol. 19(9), 2370-2380 (2001).
83. Reinartz S, Kohler S, Schlebusch H et al.: Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (Phase Ib/II). Clin. Cancer Res. 10(5), 1580-1587 (2004).
84. Berek JS, Taylor PT, Gordon A et al.: Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J. Clin. Oncol. 22(17), 3507-3516 (2004).
85. Giaccone G, Debruyne C, Felip E et al.: Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J. Clin. Oncol. 23(28), 6854-6864 (2005).
86. Sportes C, McCarthy NJ, Hakim F et al.: Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patients. Biol. Blood Marrow Transplant. 11(6), 472-483 (2005).
87. Finn OJ: Tumor immunology top 10 list. Immunol. Rev. 222, 5-8 (2008).
88. Cho WC: Contribution of oncoproteomics to cancer biomarker discovery. Mol. Cancer 6, 25 (2007).
89. Hueman MT, Dehqanzada ZA, Novak TE et al.: Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specifc antigen recurrence in high-risk prostate cancer patients. Clin. Cancer Res. 11(20), 7470-7479 (2005).
90. Gates JD, Carmichael MG, Benavides LC et al.: Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients. J. Am. Coll. Surg. 208(2), 193-201 (2009).
91. Peoples GE, Gurney JM, Hueman MT et al.: Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J. Clin. Oncol. 23(30), 7536-7545 (2005).
92. Amin A, Benavides LC, Holmes JP et al.: Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer Immunol. Immunother. 57(12), 1817-1825 (2008).
93. Peoples GE, Holmes JP, Hueman MT et al.: Combined clinical trial results of a HER2/ neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin. Cancer Res. 14(3), 797-803 (2008).
94. Humphreys RE, Adams S, Koldzic G, Nedelescu B, von Hofe E, Xu M: Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide. Vaccine 18(24), 2693-2697 (2000).
95. Xu M, Capraro GA, Daibata M, Reyes VE, Humphreys RE: Cathepsin B cleavage and release of invariant chain from MHC class II molecules follow a staged pattern. Mol. Immunol. 31(10), 723-731 (1994).
96. Kallinteris NL, Lu X, Blackwell CE, von Hofe E, Humphreys RE, Xu M: Ii-Key/ MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines. Expert Opin. Biol. Ther. 6(12), 1311-1321 (2006).
97. + tumors. Cancer Immunol. Immunother. 56(5), 601-613 (2007).
98. + T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain. Int. J. Cancer 121(9), 2031-2041 (2007).
99. Holmes JP, Benavides LC, Gates JD et al.: Results of the frst Phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J. Clin. Oncol. 26(20), 3426-3433 (2008).
100. Disis ML, Wallace DR, Gooley TA et al.: Concurrent trastuzumab and HER2/ neu-specifc vaccination in patients with metastatic breast cancer. J. Clin. Oncol. 27(28), 4685-4692 (2009).
101. Manoukian G, Hagemeister F: Denileukin diftitox: a novel immunotoxin. Expert Opin. Biol. Ther. 9(11), 1445-1451 (2009).
102. Kreitman RJ: Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies. Curr. Pharm. Des. 15(23), 2652-2664 (2009).
103. Lob S, Konigsrainer A, Rammensee HG, Opelz G, Terness P: Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat. Rev. Cancer 9(6), 445-452 (2009).
104. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN: The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14(4), 320-368 (2009).
105. Zhang L, Conejo-Garcia JR, Katsaros D et al.: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348(3), 203-213 (2003).
106. Zhang B: Targeting the stroma by T cells to limit tumor growth. Cancer Res. 68(23), 9570-9573 (2008).
107. Nefedova Y, Fishman M, Sherman S, Wang X, Beg AA, Gabrilovich DI: Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. 67(22), 11021-11028 (2007).
108. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl Acad. Sci. USA 99(25), 16168-16173 (2002).
109. Riddell SR, Greenberg PD: The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specifc T cells. J. Immunol. Methods 128(2), 189-201 (1990).
110. Bernhard H, Neudorfer J, Gebhard K et al.: Adoptive transfer of autologous, HER2-specifc, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol. Immunother. 57(2), 271-280 (2008).
111. Disis ML, Salazar LG, Coverel A et al.: Phase I study of infusion of HER2/neu (HER2) specifc T cells in patients with advanced-stage HER-2 overexpressing cancers who have received a HER2 vaccine. J. Clin. Oncol. 129S (2009) (Abstract 3000).
112. Pilon SA, Piechocki MP, Wei WZ: Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody. J. Immunol. 167(6), 3201-3206 (2001).
113. Piechocki MP, Pilon SA, Wei WZ: Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2. J. Immunol. 167(6), 3367-3374 (2001).
114. Gallo P, Dharmapuri S, Nuzzo M et al.: Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int. J. Cancer 113(1), 67-77 (2005).
115. Pupa SM, Iezzi M, Di Carlo E et al.: Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Res. 65(3), 1071-1078 (2005).
116. Cappello P, Triebel F, Iezzi M et al.: LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/ neu transgenic BALB/c mice. Cancer Res. 63(10), 2518-2525 (2003).
117. Sumida SM, McKay PF, Truitt DM et al.: Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J. Clin. Invest. 114(9), 1334-1342 (2004).
118. Sakai Y, Morrison BJ, Burke JD et al.: Vaccination by genetically modifed dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice. Cancer Res. 64(21), 8022-8028 (2004).
119. Cavallo F, Offringa R, van der Burg SH, Forni G, Melief CJ: Vaccination for treatment and prevention of cancer in animal models. Adv. Immunol. 90, 175-213 (2006).